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In the pathogenesis of cardiovascular events, true interaction (ie, synergy) between risk factors appears rare, that is, most 
studies find that risk factors act, and, thus, increase cardiovas-
cular event risk, independently of each other.1–3 However, it has 
been hypothesized that individuals with type 2 diabetes mel-
litus (DM2) are particularly prone to the detrimental effects of 
endothelial dysfunction,4–6 a key mechanism in the pathogene-
sis of atherothrombosis, and that this may explain the increased 
cardiovascular events risk in DM2. If true, this implies that 
DM2 and endothelial dysfunction interact with regard to the 
pathogenesis of cardiovascular events. That is, DM2 and endo-
thelial dysfunction may act more strongly in the presence of 
the other variable than in its absence. From a clinical point of 
view, detection of interaction between risk factors is important 
because this identifies key therapeutic targets: interventions 
aimed at such risk factors are potentially more efficacious than 
treatment of risk factors that do not interact.
The mechanism that may underlie this phenomenon is a 
bidirectional association between endothelial dysfunction 
and DM2, in which endothelial dysfunction may act as both 
cause6,7 and consequence6,8 of DM2. On the one hand, DM2 
leads to endothelial dysfunction via, amongst others, forma-
tion of advanced glycation end products, intraendothelial 
accumulation of glucose, and increased oxidative stress.6,8 On 
the other hand, endothelial dysfunction causes or aggravates 
DM2 by impairing the timely access of glucose and insulin to 
their target tissues.7 Consequently, a vicious circle may exist 
between endothelial dysfunction and DM2. In addition, DM2 
See Editorial Commentary, pp 1192–1193
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may amplify the detrimental effects of endothelial dysfunc-
tion on atherothrombosis via multiple pathways, including 
overproduction of reactive oxygen species, low-grade inflam-
mation, and increased procoagulant activity and platelet 
aggregation.9 Similar mechanisms may be operative in indi-
viduals with impaired glucose metabolism (IGM; ie, impaired 
fasting glucose and impaired glucose tolerance) or with insu-
lin resistance but with normal glucose tolerance, in whom an 
increased risk of cardiovascular events is also apparent.10,11
If the above hypothesis is correct, then the co-occurrence of 
endothelial dysfunction and DM2 will increase cardiovascular 
event risk more than expected on the basis of the presence 
of these processes alone. This phenomenon is called causal 
interaction or interaction on an additive scale12,13 and can be 
formally tested in observational data through the calculation 
of the relative excess risk due to interaction (RERI).12
To date, 2 previous studies, an earlier report of the Hoorn 
Study4 and the Framingham Offspring Study,5 have evaluated 
the joint effects of endothelial dysfunction, as determined 
by plasma biomarkers, and DM2 on incident cardiovascular 
events. In agreement with the above hypothesis, these stud-
ies showed that endothelial dysfunction was most strongly 
associated with incident cardiovascular events in individuals 
with DM2 as compared with those without DM2. However, 
these studies did not evaluate causal interaction (ie, interac-
tion on an additive scale). In addition, these studies did not 
measure flow-mediated dilatation (FMD), a key functional 
measure of endothelium-dependent, nitric oxide–mediated 
dilatation.14
In view of the above, we investigated, in a general elderly 
population, the association between endothelial dysfunction, 
as determined by FMD, and incident cardiovascular events, 
and formally tested, for the first time, whether any such asso-
ciation was stronger in individuals with DM2, IGM, and 
insulin resistance as compared with individuals with normal 
glucose metabolism (NGM) or normal insulin sensitivity (ie, 
the presence of causal interaction).
Methods
Study Design
For the present study, we used data from the 2000 Hoorn Study fol-
low-up examination. The Hoorn Study is a population-based cohort 
study of glucose metabolism and cardiovascular risk among inhabit-
ants of the municipality of Hoorn in the Netherlands. Details of the 
study have been described elsewhere.4,14,15 The Hoorn Study was 
approved by the Ethical Review Committee of the VU University 
Medical Center. Informed consent was obtained from all participants.
Brachial Artery FMD
A detailed description of the measurement of FMD and nitroglyc-
erin-mediated dilatation (NMD) is provided in the online-only Data 
Supplement (please see http://hyper.ahajournals.org).
Determination of Glucose Metabolism and Insulin 
Resistance Status
All participants, except those with previously diagnosed diabetes 
mellitus, underwent a standard 75-g oral glucose tolerance test and 
were classified as having either NGM, IGM, or DM2 according to 
the 1999 World Health Organization criteria.16 Insulin resistance was 
estimated using the homeostasis model assessment for insulin resis-
tance (HOMA2-IR) calculator (www.dtu.ox.ac.uk).
Other Measurements
Cardiovascular risk factors and prior cardiovascular disease (CVD) 
were assessed as described previously.4,14,15
Follow-Up
Follow-up was completed until January 1, 2009. Information on 
cardiovascular morbidity and mortality was extracted from medi-
cal records of general practitioners and the local hospital and clas-
sified according to the International Classification of Disease, Ninth 
Revision. We defined incident cardiovascular events (nonfatal and fatal 
combined) as International Classification of Disease, Ninth Revision 
codes: 410 to 414 (coronary heart disease), 427 to 428 (heart failure), 
431 to 438 (cerebrovascular disease), 440 to 443 (arterial disease), 
798 (sudden death), and International Classification of Disease, Ninth 
Revision clinical modification code 36 (coronary arterial procedures). 
Data on the participants’ vital status were collected from the munici-
pal population register. We determined for each participant whether 
death had occurred during follow-up and, if so, the date when death 
occurred.
Statistical Analyses
All analyses were performed with R statistical software (version 2.15.2). 
For insulin resistance status, individuals were classified by the highest 
HOMA2-IR tertile versus the lower tertiles combined. The lower tertiles 
were combined because results for these tertiles did not materially dif-
fer from each other in all analyses (ie, there was a nonlinear interaction 
between FMD and HOMA2-IR levels, see below). In all analyses, FMD 
was adjusted for baseline diameter, flow increase after cuff release, 
and NMD. Results were adjusted for NMD, a measure of endothelial-
independent vasodilatation, because less FMD may be because of 
impaired endothelial and endothelial-independent (smooth muscle cell) 
function.14 Cox proportional hazard models were used to estimate the 
association between FMD and incident cardiovascular events. First, the 
association between FMD and cardiovascular events was evaluated in 
the total study population. This association was adjusted for age and 
sex (cohort stratifying variables, model 1) and additionally for prior 
CVD, body mass index, total/high-density lipoprotein cholesterol, tri-
glycerides, hypertension, estimated glomerular filtration rate, physical 
activity, smoking habits, the use of antihypertensive and lipid-lowering 
medication (potential confounders; model 2); glucose metabolism sta-
tus (ie, DM2, IGM, and NGM; model 3); and insulin resistance status 
(ie, highest HOMA2-IR tertile and lower 2 tertiles combined; model 4). 
Second, analyses were repeated after stratification for glucose metabo-
lism or insulin resistance status. Third, we investigated the presence of 
potentially causal interactions on an additive scale (ie, when risk fac-
tors act synergistically in causing disease).13 In Cox regression analysis, 
however, statistical interaction is exponential and, therefore, multiplica-
tive. To nevertheless evaluate the presence of additive interaction, we 
calculated the RERI.12 RERI represents the risk that is in excess of what 
would be expected if there had been no additive interaction. An RERI >0 
indicates positive additive interaction.12 In these analyses, adjustments 
were made for the same sets of potential confounders as described for 
the Cox regression models. Confidence intervals of the RERI were esti-
mated by using a bootstrap method with 10 000 samples.12 Finally, we 
also calculated the presence of any multiplicative interaction by adding, 
to our Cox regression models, product terms between FMD and DM2, 
IGM, and insulin resistance.
Results
Study Population
Of the 648 participants, qualitatively sufficient ultrasound 
examinations were obtained in 492 individuals. Data were 
missing for logistical reasons (n=49) and poor definition of the 
arterial wall because of obesity (n=107). In addition, partici-
pants were excluded when data on glucose metabolism status 
(n=8) or cardiovascular event follow-up were missing (n=39; 
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and 33 did not give permission to access their medical files or to 
contact their general practitioner). Thus, 445 participants were 
eligible for the present analyses. Individuals without follow-up 
data did not differ from the study population (data not shown).
Clinical Characteristics
Table 1 shows the baseline characteristics of the study population 
according to cardiovascular event status. The median duration 
of follow-up was 7.6 years (range 0.2–8.9). A total of 106 par-
ticipants (42 NGM, 33 IGM, and 31 DM2) had a cardiovascular 
event; 12 (11.3%) of which were fatal. A total of 48 participants 
had a coronary heart disease event (16 NGM, 19 IGM, and 13 
DM2), 35 had a cerebrovascular event (16 NGM, 10 IGM, and 9 
DM2), and 23 had a cardiovascular event other than a coronary 
heart disease or cerebrovascular event (eg, peripheral arterial dis-
ease or heart failure). The incidence rate of cardiovascular events 
was 3.1% per year. Individuals with an incident cardiovascular 
event were older and more often men. In addition, these individu-
als suffered more often from DM2, had greater insulin resistance 
as determined by HOMA2-IR, and a less favorable cardiovascu-
lar risk profile (Table 1). In addition, individuals with a cardio-
vascular event had less FMD, a smaller baseline diameter, and a 
lower flow increase after cuff release (Table 1).
Association Between FMD and Incident 
Cardiovascular Events
Multivariable Cox regression analysis showed that FMD 
was not significantly associated with incident cardiovascu-
lar events in the overall population (Table 2, models 1–4). 
However, when the analyses were repeated stratified accord-
ing to glucose metabolism or insulin resistance status, the 
results showed that, after adjustment for potential confound-
ers, less FMD was associated with cardiovascular events in 
individuals with DM2 and IGM, but not in individuals with 
NGM (Table 2, model 2; also illustrated in Figure, panel A). 
Similarly, less FMD was associated with cardiovascular events 
among those in the highest HOMA2-IR tertile, but not among 
those in the lower 2 tertiles combined (Table 2, model 2; also 
illustrated in Figure, panel B). These results did not materially 
change when we additionally adjusted glucose metabolism 
and insulin resistance status for each other (models 3 and 4).
Interaction Analyses
When the analyses were repeated to test for additive interac-
tion between FMD and glucose metabolism status, the results 
showed that, after adjustment for potential confounders, the 
RERI, per 1 SD less FMD, was 0.64 (95% confidence inter-
val [CI], −0.35–1.32) for DM2 versus NGM and 0.68 (95% 
CI, −0.07–1.93) for IGM versus NGM, respectively (Table 2, 
model 2). This means that the hazard ratios (HRs) for inci-
dent cardiovascular events in DM2 and IGM were, per 1 SD 
less FMD, 0.64 and 0.68 higher, respectively, than if there 
had been no interaction between FMD and DM2 or IGM. 
Similarly, the RERI, per 1 SD less FMD, was 0.73 (95% CI, 
0.30–1.34) for the highest HOMA2-IR tertile versus the lower 
2 tertiles combined (Table 2, model 2).
When the analyses were repeated to test for multiplica-
tive interaction, the results showed that, after adjustment for 
potential confounders, the HRs, per 1 SD less FMD, for the 
Table 1. Clinical Characteristics of the Study Population at 
Baseline According to Incident Cardiovascular Event Status
Clinical  
Characteristics
Participants Without a 
Cardiovascular Event, 
n=339 (76.2%)




Age, y 68.5±6.2 71.4±6.1
Women 55.5 35.8
Smoking habits
  Current smoker 10.9 21.7
  Former smoker 44.0 49.1
  Nonsmoker 45.1 29.2
Physical activity (MET hours/week) 82 (49–128) 77 (48–125)
Prior cardiovascular disease 47.5 63.2
Glucose metabolism status
  Type 2 diabetes mellitus 20.9 29.2
  Impaired glucose metabolism 26.8 31.1
  Normal glucose metabolism 52.3 39.7
Insulin resistance status
  HOMA2-IR 1.00 (0.80–1.50) 1.20 (0.80–1.63)
  HOMA2-IR tertile 3 31.0 37.3
  HOMA2-IR tertile 2 38.8 31.4
  HOMA2-IR tertile 1 30.2 31.3
Body mass index, kg/m2 26.7±3.3 27.2±3.4
Systolic blood pressure, mm Hg 141±20 148±21
Diastolic blood pressure, mm Hg 82±11 83±11
Hypertension 62.8 79.2
HbA1c, mmol/mol 41±7 44±9
HbA1c, % 5.9±0.7 6.2±0.8
Total cholesterol, mmol/L 5.8±1.0 5.8±1.1
LDL cholesterol, mmol/L 3.7±0.9 3.8±0.9
HDL cholesterol, mmol/L 1.5±0.4 1.3±0.4
Triglycerides, mmol/L 1.2 (0.9–1.7) 1.4 (1.1–1.8)




creatinine ratio >2 mg/mmol)
10.9 20.0
Medication use
  Lipid-lowering medication 12.4 19.8
  Antihypertensive medication 28.9 44.3
Flow-mediated dilatation
Flow-mediated dilatation, mm 0.19±0.15 0.14±0.20
Flow-mediated percentage 
change in diameter, %
4.3±3.7 3.1±4.0
Baseline diameter, mm 4.59±0.75 4.83±0.69
Flow increase after cuff release, % 91±45 79±40






Data are presented as percentage, mean±SD, or median (interquartile 
range). CVD indicates cardiovascular disease; HbA1c, hemoglobin A1c; HDL, 
high-density lipoprotein; HOMA2-IR, homeostasis model assessment for insulin 




 http://ahajournals.org by on Septem
ber 16, 2021
1302  Hypertension  December 2014
product terms between FMD and DM2 or IGM versus NGM 
were 1.96 (95% CI, 1.21–3.17) and 1.76 (95% CI, 1.03–2.98), 
respectively (Table 2, model 2). This means that the HRs for 
incident cardiovascular events in DM2 and IGM were, per 1 
SD less FMD, 1.96× and 1.76× higher, respectively, than if 
there had been no multiplicative interaction between FMD 
and DM2 or IGM. Similarly, the HR, per 1 SD less FMD, for 
the product terms between FMD and the highest HOMA2-IR 
tertile versus the lower 2 tertiles combined was 2.25 (95% CI, 
1.53–3.32) (Table 2, model 2). These results did not materially 
change when we additionally adjusted glucose metabolism 
and insulin resistance status for each other (models 3).
Additional Analyses
There was no additive or multiplicative interaction between 
FMD and hemoglobin A1c, fasting, or postload glucose in the 
association with cardiovascular events (data not shown). In 
addition, the results of the interaction analyses between FMD 
and DM2, IGM, and insulin resistance did not materially 
change when we additionally adjusted for hemoglobin A1c, 
fasting, or postload glucose (data not shown).
All analyses were then repeated with incident cardiovas-
cular events as the outcome, but with incident heart failure 
(n=9) excluded from the definition of cardiovascular events. 
The results of these analyses were qualitatively similar to the 
analyses with total incident cardiovascular events as the out-
come (please see http://hyper.ahajournals.org; Table S1 in the 
online-only Data Supplement).
Next, all analyses were repeated with all-cause mortality 
as the outcome. These analyses showed that FMD was not 
associated with all-cause mortality. In addition, there was no 
additive or multiplicative interaction between FMD and DM2, 
Table 2. Association Between Flow-Mediated Dilatation and Incident Cardiovascular Events: Analyses in the Total Study 
Population and Stratified Analyses and Interaction Analyses With Glucose Metabolism and Insulin Resistance Status
Models
Analyses in the Total Study  
Population and Stratified Analyses Interaction Analyses
HRs, 95% CIs*
Additive Scale Multiplicative Scale
RERIs,  
95% CIs*
HRs of Product  
Terms, 95% CIs*
Total study population
Model 1 1.31 (1.01–1.70) … …
Model 2 1.18 (0.89–1.55) … …
Model 3: Model 2 + 
glucose metabolism status
1.19 (0.90–1.57) … …
Model 4: Model 2 + insulin 
resistance status
1.18 (0.88–1.57) … …
Glucose metabolism status (DM2, IGM, and NGM)
Model 1 DM2 1.56 (1.13–2.17) DM2 vs NGM 0.69 (−0.34–1.87) 1.61 (1.03–2.53)
IGM 1.49 (0.97–2.29) IGM vs NGM 0.68 (−0.17–1.98) 1.54 (0.92–2.59)
NGM 0.96 (0.68–1.36)
Model 2 DM2 1.69 (1.14–2.52) DM2 vs NGM 0.64 (−0.35–1.32) 1.96 (1.21–3.17)
IGM 1.50 (0.95–2.37) IGM vs NGM 0.68 (−0.07–1.93) 1.76 (1.03–2.98)
NGM 0.85 (0.63–1.16)
Model 3: Model 2 + insulin 
resistance status
DM2 1.73 (1.14–2.62) DM2 vs NGM 0.74 (−0.45–1.57) 2.03 (1.23–3.33)
IGM 1.57 (0.96–2.57) IGM vs NGM 0.76 (−0.01–2.06) 1.88 (1.07–3.30)
NGM 0.84 (0.61–1.14)
Insulin resistance status (HOMA2-IR tertiles)
Model 1 T3 1.70 (1.32–2.20) T3 vs T1-2† 0.79 (0.37–2.01) 1.75 (1.21–2.51)
T1-2† 0.98 (0.73–1.30)
Model 2 T3 1.92 (1.42–2.60) T3 vs T1-2† 0.73 (0.30–1.34) 2.25 (1.53–3.32)
T1-2† 0.85 (0.65–1.12)
Model 3: Model 2 + 
glucose metabolism status
T3 1.93 (1.42–2.62) T3 vs T1-2† 0.73 (0.30–1.39) 2.25 (1.52–3.32)
T1-2† 0.86 (0.65–1.12)
Model 1: adjusted for age, sex, baseline diameter, flow increase after cuff release, and nitroglycerin-mediated dilatation.
Model 2: Model 1+prior cardiovascular disease, body mass index, total/HDL cholesterol, triglycerides, hypertension, estimated glomerular filtration rate, physical 
activity, smoking habits, and the use of antihypertensive and lipid-lowering medication.
CI indicates confidence interval; DM2, type 2 diabetes mellitus; HOMA2-IR, homeostasis model assessment for insulin resistance; HRs, hazard ratios; IGM, impaired 
glucose metabolism; NGM, normal glucose metabolism; RERIs, relative excess risk due to interactions; and T, tertile.
*Hazard ratios (HRs) and relative excess risk due to interactions (RERIs) are indicated per 1 SD (0.17 mm) less flow-mediated dilatation. RERI >0 indicates the 
presence of positive additive interaction, and HR of product term >1 indicates positive multiplicative interaction.
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IGM, or insulin resistance in the association with all-cause 
mortality (please see http://hyper.ahajournals.org; Table S2).
Endothelial function is closely linked to low-grade inflam-
mation. Any association of endothelial dysfunction with 
incident cardiovascular events and mortality may, thus, be 
dependent on low-grade inflammation. We therefore deter-
mined circulating biomarkers of low-grade inflammation 
(high-sensitivity C-reactive protein, serum amyloid A, inter-
leukin-6, interleukin-8, tumor necrosis factor-α, and soluble 
intracellular adhesion molecule-1) and constructed a sum-
marizing low-grade inflammation Z-score as described pre-
viously.17 When we additionally adjusted the results for this 
Z-score, results did not materially change (data not shown).
Estimation of insulin resistance based on HOMA2-IR may 
be less accurate in individuals treated with insulin.18 When we 
excluded these individuals (n=10) from the analyses, however, 
results did not materially change (data not shown).
The associations between FMD and incident cardiovascu-
lar events may differ according to the presence of prior CVD. 
However, no interaction was observed on an additive (RERI 
−0.17 [95% CI, −1.09–0.74]) or a multiplicative scale (HR for 
the product term between FMD and prior CVD versus no prior 
CVD was 0.82 [95% CI, 0.50–1.33]).
Finally, the associations between FMD and incident car-
diovascular events may differ according to DM2 duration. 
However, no interaction was observed on an additive (RERI 
−0.03 (95% CI, −0.25–0.32)) or a multiplicative scale (HR for 
the product term between FMD and DM2 duration was 0.96 
(95% CI, 0.90–1.04).
Discussion
This population-based study is the first that formally tests the 
joint effect, on incident cardiovascular events, of FMD on 
the one hand and DM2, IGM, and insulin resistance on the 
other. We observed that FMD was most strongly associated 
with cardiovascular events in individuals with DM2 or insu-
lin resistance, less strongly in IGM, and not associated with 
incident cardiovascular events in individuals with NGM or 
normal insulin sensitivity. Importantly, the increased cardio-
vascular events risk of the joint effect of endothelial dysfunc-
tion and DM2, IGM, or insulin resistance was greater than 
what would have been expected had the effect of FMD on the 
one hand and glucose metabolism or insulin resistance status 
on the other acted independently of each other (as indicated 
by a RERI >0), demonstrating the presence of interaction or 
synergy between endothelial dysfunction and impairment of 
glucose metabolism with respect to cardiovascular event risk.
The present study defined endothelial dysfunction as 
impaired endothelium-dependent FMD, which is a key func-
tional estimate of endothelial function.14 The study thereby 
extends previous studies4,5 on the joint effects of endothelial 
dysfunction and DM2, IGM, or insulin resistance on inci-
dent cardiovascular events, which used plasma biomarkers 
to define endothelial dysfunction and showed multiplicative 
interaction between endothelial dysfunction and DM2. No 
information was, however, provided on an additive interaction 
scale (ie, potentially causal interaction).12,13 The present study, 
therefore, provides additional and strong evidence in favor of 
a causal interaction between endothelial dysfunction on the 
one hand and DM2, IGM, and insulin resistance on the other 
in the pathogenesis of cardiovascular events.
Causal interaction between 2 factors means mutual depen-
dence in causing disease, ie, such factors are component 
causes in the same causal model. Rothman13 and others12 have 
argued that potentially causal interaction needs to be evalu-
ated as departure from additivity rather than departure from 
multiplicativity. In the present study, interaction was present 
on an additive (as indicated by RERI) as well as on a multipli-
cative scale (as indicated by interaction terms in the regression 
analyses). Not all interaction tests were, however, statistically 
significant. This may be because of the fact that, in general, 
these tests are limited by relatively low statistical power.
The mechanism that may underlie this interaction is the 
presence of a vicious circle between endothelial dysfunc-
tion and DM2, IGM, and insulin resistance,6 with, on the one 
hand, DM2, IGM, and insulin resistance causing endothelial 
Figure. Associations (hazard ratios) of flow-mediated dilatation with incident cardiovascular events stratified according to (A) glucose 
metabolism status (ie, type 2 diabetes mellitus [DM2], impaired glucose metabolism [IGM], and normal glucose metabolism [NGM]) 
and (B) insulin resistance status (ie, HOMA2-IR tertiles). All results are adjusted for potential confounders (see text). Solid lines indicate 
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dysfunction and, on the other, endothelial dysfunction causing 
insulin resistance, IGM, and DM2.7,8 There is abundant evi-
dence that DM2, IGM, and insulin resistance cause endothelial 
dysfunction,9 but evidence for the reverse process is relatively 
recent.7 However, insulin normally can redirect blood flow in 
skeletal muscle from non-nutritive capillaries to nutritive capil-
laries and, thereby, increase insulin-mediated glucose uptake.19 
These processes are impaired by endothelial dysfunction.7 In 
addition, endothelial dysfunction may also cause apoptosis 
of β-cells in the pancreas,20 which decreases insulin secretory 
capacity and, therefore, may, further impair glucose metabo-
lism. In addition, DM2 may amplify the detrimental effects 
of endothelial dysfunction on atherothrombosis.9 Hence, the 
co-occurrence of these processes may accelerate atherothrom-
bosis and, thus, increase cardiovascular event risk more than 
expected from the presence of these processes alone.
In the present study, glucose metabolism and insulin resis-
tance states interacted with endothelial dysfunction indepen-
dently of each other. This suggests that mechanisms associated 
with DM2 and IGM other than insulin resistance may play a 
role in the interaction with endothelial dysfunction, such as 
advanced glycation end products, oxidative stress, and dia-
betic dyslipidemia.9
Somewhat surprisingly, estimates of hyperglycemia (ie, 
hemoglobin A1c, fasting, or postload glucose) did not interact 
with endothelial dysfunction in the association with cardiovas-
cular events. This finding may have several explanations. First, 
only a single measurement of (baseline) variables was available 
in the present study. Baseline glucose levels may not accurately 
reflect exposure during follow-up. Second, glucose levels may 
not accurately reflect the mechanisms by which hyperglycemia 
leads to endothelial dysfunction and cardiovascular events (ie, 
advanced glycation end products and oxidative stress).9 Third, 
it has been suggested that glucose variability21 and episodes of 
hypoglycemia22 may be more strongly associated with endothe-
lial dysfunction than mean blood glucose levels (ie, hemoglobin 
A1c). Nevertheless, we cannot exclude the play of chance.
From a clinical point of view, the synergistic association 
between endothelial dysfunction and DM2 is important as 
endothelial dysfunction may act at least partially as the under-
lying phenomenon which might explain the 2 to 3× higher 
cardiovascular events risk seen in DM2. This suggests that 
endothelial dysfunction is a key therapeutic target for lower-
ing of CVD risk in DM2. In addition, the fact that an interac-
tion was already present in individuals with IGM and insulin 
resistance identifies endothelial dysfunction as an early thera-
peutic target even before DM2 is present. This is in accordance 
with the hypothesis that insulin resistance, IGM, and DM2 are 
manifestations of a continuous disease process to increase the 
risk of cardiovascular events (ticking clock hypothesis).10,11
Our study had some limitations. First, it is likely that sur-
vival bias affected our results, ie, it is probable that individuals 
who died before the start of the present study were those with 
the strongest association between endothelial dysfunction and 
DM2 and incident cardiovascular events. Such bias would, 
however, have led to an underestimation of the reported asso-
ciations and may explain why we did not find an association 
between FMD and incident cardiovascular events in individu-
als with NGM. Second, the cardiovascular event rate in the 
present study population at high cardiovascular risk was in 
accordance with previous studies.10 However, a relatively 
low number (11.3%) of participants died of a cardiovascular 
event, which may reflect a survival effect and may be because 
of the high quality of CVD management in the Netherlands. 
This low fatal cardiovascular event rate may explain the lack 
of an interaction between endothelial dysfunction and glu-
cose metabolism or insulin resistance in the association with 
all-cause mortality. Third, the present study had insufficient 
power to evaluate interaction, with regard to specific cardio-
vascular events, between FMD on the one hand and glucose 
metabolism status en insulin resistance on the other. Finally, 
only a single (baseline) measurement of FMD was available. 
Baseline FMD may not accurately reflect exposure during 
follow-up, and this may have led to an underestimation of the 
reported associations.
In conclusion, the present study shows that individuals with 
DM2, IGM, or insulin resistance are particularly sensitive to 
the adverse cardiovascular effects of endothelial dysfunction.
Perspectives
In the pathogenesis of cardiovascular events, true interaction 
between risk factors has rarely been identified. The present 
study shows, for the first time, the presence of interaction (ie, 
synergy) between endothelial dysfunction and DM2, IGM, 
and insulin resistance with respect to cardiovascular event 
risk. This suggests that endothelial dysfunction is a key ther-
apeutic target for the prevention of cardiovascular events in 
individuals with DM2, IGM, or insulin resistance.
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What Is New?
•	 In the pathogenesis of cardiovascular events, true interaction between 
risk factors has rarely been identified.
•	However, it has been suggested that endothelial dysfunction and type 2 
diabetes mellitus (DM2) act synergistically (ie, interact) in the develop-
ment of cardiovascular events.
•	Earlier studies indeed showed that endothelial dysfunction, as deter-
mined by plasma biomarkers, was most strongly associated with inci-
dent cardiovascular events in individuals with DM2 as compared with 
those without DM2.
•	 However, previous studies did not evaluate causal interaction (ie, interac-
tion on an additive scale) and did not measure flow-mediated dilatation, a 
key functional measure of endothelium-dependent, NO-mediated dilatation.
What Is Relevant?
•	The present prospective population-based study investigated the associ-
ation between endothelial dysfunction, as determined by flow-mediated 
dilatation, and incident cardiovascular events and formally tested wheth-
er any such association was stronger in individuals with DM2, impaired 
glucose metabolism, and insulin resistance as compared with individuals 
with normal glucose metabolism or normal insulin sensitivity.
Summary
The results of the present study showed that endothelial dysfunc-
tion and DM2, impaired glucose metabolism, or insulin resistance 
synergistically increase cardiovascular event risk. This identifies en-
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